DESCRIPTION OF HIV/AIDS PATIENTS IN NEPAL: COMPARISON OF THOSE TREATED WITH AND THOSE NOT TREATED, AND COMPARISON OF THOSE WHOSE TREATMENT IS OBSERVED AND NOT OBSERVED



Mr. Sushil Yadav

A Thesis Submitted in Partial Fulfillment of the Requirements

for the Degree of Master of Public Health in Health Systems Development

College of Public Health

Chulalongkorn University

Academic Year 2004

ISBN 974-9599-82-9

Copyright of Chulalongkorn University

Thesis Title	: Description of HIV/AIDS Patients in Nepal: Comparison of Those Treated With Those Not Treated, and Comparison of Those Whose Treatment is Observed and Not Observed
Ву	: Mr. Sushil Yadav
Program	: Health Systems Development
Thesis Advisor	: Robert Sedgwick Chapman, M.D., M.P.H.
-	by the College of Public Health, Chulalongkorn University in Partial Requirements for the Master's Degree
	Dean of the College of Public Health Chitr Sitthi-amorn, M.D., M.Sc., Ph.D.)
THESIS COMMI	TTEE
	Rh Sm Chairperson
(R	atana Somrongthong, M.A., Ph.D.)
	Roth S. Chapman Thesis Advisor
(Re	obert Sedgwick Chapman, M.D., M.P.H.)
	Olan le Member
(A:	ssociate Professor Narin Hiransuthikul, M.D., M.P.H.)

(Emeritus Professor Edgar J. Love, M.D., Ph.D.)

PH: 042425 : MAJOR HEALTH SYSTEMS DEVELOPMENT PROGRAMME KEY WORDS : HIV/ ARV/ NON-DAART/ DAART/ WELL BEING/ NEPAL

SUSHIL YADAV: DESCRIPTION OF HIV/AIDS PATIENTS IN NEPAL: COMPARISON OF THOSE TREATED WITH THOSE NOT TREATED, AND COMPARISON OF THOSE WHOSE TREATMENT IS OBSERVED AND NOT OBSERVED. THESIS ADVISOR: ROBERT SEDGWICK CHAPMAN, M.D, M.P.H., 86 pp. ISBN 974-9599-82-9

To date, relatively few studies have assessed outcomes of antiretroviral therapy in developing countries. In Nepal, currently the Ministry of Health is implementing Highly Active Anti-retroviral Therapy (HAART or non-DAART) in a government hospital. This treatment is self-administered by the patient, and 25 patients (11 females and 14 males) are taking it. At the same time Directly Observed Antiretroviral Therapy (DAART) is implemented in 17 HIV-positive females by a non-governmental organization, Maiti Nepal. This study compared time trends in CD4+ T cell counts, and current quality of life, between these 42 treated patients and a control group of 42 untreated HIV-positive females who also lived at Maiti Nepal. The study also compared CD4+ trends, accessibility of and adherence to treatment, and current quality of life between treated patients on DAART and non-DAART.

After one year of treatment, mean CD4+ count had increased from baseline in the DAART and non-DAART groups. Over this year, mean CD4+ cell count decreased in subjects without treatment. This difference was statistically significant (alpha=.05, p<.001). In treated patients, CD4+ counts increased significantly more with DAART than non-DAART (p<.001). The DAART patients had better access and adherence to treatment than the non-DAART patients. Respondents on DAART had a statistically significantly lower rate of side effects (47%) than respondents on Non-DAART (84.4%) (p<.05). Also, 88.2% of patients on DAART never missed their dosage in the last 2 weeks, in comparison to only 28% of non-DAART patients (p<.001). Patients on DAART had more knowledge about treatment adherence and side effects, and about drug resistance, than did non-DAART patients. The self-rated overall quality of life was significantly higher among patents without treatment than with treatment. Among treated patients, scores for specific aspects of quality of life were generally higher in the DAART group than the non-DAART group. Results were generally similar when males were included in, and excluded from, analysis. In conclusion, the results suggest that accessibility is an important predictor of treatment adherence in Nepal. More broadly, results suggest that DAART would be the most useful method to maximize effectiveness of ARV treatment in Nepal.

Field of study Health Systems Development Student's signature

Academic year 2004 Advisor's signature Robert Student's signature

ACKNOWLEDGEMENTS

First of all, I would like to express my sincere gratitude and deep appreciation to Dr. Robert S. Chapman, my thesis advisor, for his guidance, invaluable advice, supervision and encouragement throughout all phases of this study.

I would like to thank Dr. Ratana Somrongthong for her valuable time and suggestions for my proposal development, and she provided me valuable information about instrument to collect data.

I am also very grateful to Dr. Narin Hiransuthikul, my external advisor, for his technical comments on the HIV research, and giving me valuable information about HIV/AIDS research.

I would like to express my gratitude Professor Edgar J. Love, M.D., Ph.D., University of Calgary, Canada for his valuable advise for thesis improvement.

I would like to thanks to Dr. Valaikanaya Plasai for helping me to get funding for my research.

My special thanks must go to doctors and nurses who helped me with data collection as the informants or data collectors in the study sites.

I would like to thank all my teachers of college of public health for giving me good lectures and valuable instructions. And also, I want to thank all staff of the college for their kindness and support for my study throughout the course.

I would to thank Mr. Tara Singh Bam for helping me during data collection, Mr. Sujan for helping me for translation of questionarrires, let me also thank Sushil Koirala at Mahidol University.

Lastly but not least, I would like to convey my deepest love and thanks to my parents and my wife for giving me mental support and encouraged me for the successful completion of MPH study.

TABLE OF CONTENTS

		P	age
ABST	RA(CT	iii
ACKN	4OM	/LEGDEMENTS	iv
TABL	ΕO	F CONTENTS	v
LIST	OF 7	TABLES	viii
LIST	OF F	FIGURES	xi
ABBR	REVI	IATIONS	xii
CHAI	PTE	R I INTRODUCTION	1
1	1.1	Study Outline	1
1	1.2	Background	2
1	1.3	Justification of the Research	7
1	1.4	Problem Statement_	9
1	1.5	Purpose of the Study	9
1	1.6	Objective of the Study	10
1	1.7	Research Questions	11
1	8.1	Research Hypothesis	11
1	.9	Definition of Major Variables	12
1	.10	Conceptual Framework	14
СНАР	PTE	R II LITERATURE REVIEW	15
2	2.1	Antiretroviral Treatment_	15
2	2.2	The CD4+Test	16

	2.3	The Viral Load Test	17
	2.4	Adherence	18
	2.5	Side-effects	19
	2.6	Literature Review	20
	2.7	Literature Review from Previous Study	23
СНА	APTE	R III RESEARCH METHODOLOGY	29
	3.1	Research Design	29
	3.2	Site of Study	29
	3.3	Population and Sample_	30
	3.4	Sampling Method	30
	3.5	Sample Size	31
	3.6	Research Instrument	31
	3.7	Validity and Reliability	32
	3.8	Method of Data Collection	32
	3.9	Data Analysis	33
	3.10	Major Goals of Analysis_	34
	3.11	Ethical Considerations	35
CHA	APTE	R IV RESULTS	36
	4.1	General Data from Respondent	36
	4.2	Finding of Retrospective Study	44
	4.3	Finding of Satisfied with Knowledge about Treatment, Adherence, and Resistance	47
	4.4	Finding of Quality of Life of Respondents Under Treatment and Without Treatment	50

CHAPTER	R V DISCUSSION, CONCLUSION	
	AND RECOMMENDATION :	55
5.1 I	Discussion	55
5.2 I	Limitation of Study (54
5.3	Conclusions	55
5.4 I	Recommendation (56
REFERENCES		57
APPENDIC	CES	59
APPENDIX	X A Questionnaire on HIV	70
APPENDIX	XB Questionnaire on Quality of Life	78
APPENDIX	C Informed Consent Form 8	30
APPENDIX	X D Data collection form	31
CHIPDICH	I UM VITAE	24

LIST OF TABLES

		Page
Table 4.1:	Distribution of respondents by Socio-demographic Characteristics	37
Table 4.2:	Gender distribution of the respondents	38
Table 4.3:	Differences between people with and without treatment	
	by age and years since diagnosed with HIV/AIDS	39
Table 4.4:	Differences between people within DAART and Non-DAART	
	treatment by age and year of diagnosed with HIV/AIDS	39
Table 4.5:	correlation between age and years since diagnosis with HIV/AIDS	
	among respondents in three groups.	40
Table 4.6:	differences between DAART, Non-DAART	
	and without treatment in terms of educational qualification.	40
Table 4.7:	The frequency and percentage distribution of patients	
	by problems with getting information about anti-HIV	
	treatment under Non-DAART and DAART	41
Table 4.8:	All Subject on Rx Problem in relation to knowledge about	
	anti-retroviral therapy (ART), and about taking ART regularly	41
Table 4.9:	The frequency and percentage distribution of respondents	
	by overall satisfaction of knowledge about anti-HIV	
	treatment under Non-DAART and DAART	42
Table 4.10:	The frequency and percentage distribution of respondents	
	by satisfaction in of knowledge about adherence under	
	Non-DAART and DAART	42
Table 4.11:	The frequency and percentage distribution of respondents	
	by overall satisfaction of knowledge about resistance	
	to anti-HIV treatment under Non-DAART and DAART	43

1 able 4.12:	Number, mean and standard deviation of respondents under Non-DAART, DAART and without treatment by year of diagnosed with HIV/AIDS	43
Table 4.13:	Comparison between respondents with and without illness since diagnosed with HIV	44
Table 4.14:	Change in CD4+ in all subjects with and without ART	46
Table 4.15:	Change in CD4+ in females with and without ART	46
Table 4.16:	Change in CD4+ in treated subjects with and without DAART	46
Table 4.17:	Change in CD4+ in treated females with and without DAART	47
Table 4.18:	Comparison between all respondents with and without DAART in terms of side effects	47
Table 4.19:	Comparison among female respondents with and without DAART in terms of side effects	48
Table 4.20:	Comparison between all respondents with and without DAART missed dosage in two weeks.	48
Table 4.21:	Comparison between Female respondents with and without DAART missed dosage in two weeks	49
Table 4.22:	Comparison between with and without DAART in terms of problem with access to treatment	49
Table 4.23:	Comparison of overall quality of life among patients under Non-DAART and DAART treatment	50
Table 4.24:	Comparison of overall quality of life among patients under treatment and without treatment	50
Table 4.25:	Comparison of overall satisfaction level of health among respondent under Non-DAART and DAART treatment	51
Table 4.26:	Comparison of overall satisfaction level of health among respondents under treatment and without treatment	51
Table 4.27:	Quality of life of all respondents by domain	52

Table 4.28:	Quality of life among female respondents by domain	53
Table 4.29:	Quality of life among respondents under DAART	
	and Non-DAART by domain	53
Table 4.30:	Quality of life among female respondents under DAART	
	and Non-DAART by domain	54

LIST OF FIGURE

	P	age
Figure 1.1:	Conceptual framework	14
Figure 4.1:	Baseline and follow-up mean CD4+ cell counts per mm3 by treatment status, all subjects	44
Figure 4.2:	Baseline and follow-up mean CD4+ cell counts per mm3	
	by treatment status, females only	45

ABBREVIATIONS

AIDS : Acquired immune deficiency syndrome

ARH : Adolescent reproductive health

ART : Anti-retroviral Therapy

CBO : Community-based organization

CBS : Central Bureau of Statistics

CDC : Centers for Disease Control and Prevention

CEDPA : Centre for Development and Population Activities

CREHPA : Center for Research on Environmental Health and

Population Activities

DAART : Directly Administered Antiretroviral Therapy

DoHS : Department of Health Services
DPHO : District Public Health Office

EDCD : Epidemiology and Disease Control Division

EHP : Environmental Health Project
FHI : Family Health International

GIS : Geographic Information System

HAART (or non-DAART) : Highly Active Antiretroviral Therapy (not directly

observed)

HIV : Human immuno-deficiency virus
HMG/N : His Majesty's Government of Nepal

IDUs : Injecting Drug Users

IEC : Information, education, and communication

MoH : Ministry of Health

NCASC : National Center for AIDS and STD Control

NGO : Non-Governmental Organization
STD : Sexually transmitted disease
STI : Sexually transmitted infection

SWs : Sex-workers

UNAIDS : Joint United Nations Programme on HIV/AIDS

USAID : United States Agency for International Development

VDC : Village development committee

WHO : World Health Organization